Can escitalopram (Lexapro) be prescribed concurrently with hydroxyzine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Lexapro and Hydroxyzine Be Prescribed Together?

Yes, escitalopram (Lexapro) can be prescribed with hydroxyzine, but this combination requires caution due to the risk of QT interval prolongation from both medications. 1, 2

Key Safety Considerations

QT Prolongation Risk

Both medications carry warnings about QT prolongation and potential for Torsade de Pointes (TdP):

  • Escitalopram has documented QT-prolonging effects, leading the FDA and EMA to limit maximum recommended doses (further reduced in patients >60 years) 3, 2
  • Hydroxyzine has post-marketing reports of QT prolongation and TdP, with the FDA label explicitly cautioning against concomitant use with drugs known to prolong the QT interval, specifically mentioning certain antidepressants including citalopram and fluoxetine 1

The 2014 European Heart Journal guideline classifies SSRIs (including escitalopram) as having propensity for QT prolongation, with registry studies showing increased cardiac arrest risk (OR 1.21 for SSRIs overall) 3.

When This Combination May Be Appropriate

The combination can be justified when:

  • Anxiety symptoms are severe and require immediate management alongside depression treatment
  • The patient has been screened for cardiac risk factors
  • Benefits outweigh the additive QT prolongation risk

Research evidence supports this approach: A 2022 study in children/adolescents with ARFID demonstrated that SSRI+hydroxyzine was safe and effective, with similar improvements in anxiety and fear outcomes compared to SSRI alone, even in patients with higher baseline anxiety 4.

Pre-Prescription Requirements

Before prescribing this combination, assess for:

  • Pre-existing heart disease or structural cardiac abnormalities
  • Personal or family history of long QT syndrome or sudden cardiac death
  • Recent myocardial infarction, uncompensated heart failure, or bradyarrhythmias
  • Electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia)
  • Concomitant medications that prolong QT interval
  • Age >60 years (higher risk with escitalopram)

Obtain baseline ECG if any risk factors are present 1.

Dosing Strategy

  • Start escitalopram at 10 mg daily; maximum 20 mg daily (10 mg maximum if >60 years or hepatic impairment) 2
  • Use lowest effective hydroxyzine dose, particularly in elderly patients who are more susceptible to sedation and confusion 1
  • Consider hydroxyzine for short-term or as-needed use rather than chronic daily dosing to minimize cumulative cardiac risk

Additional Drug Interaction Concerns

CNS Depression: Hydroxyzine potentiates CNS depressants. Warn patients about:

  • Increased sedation and drowsiness
  • Impaired ability to drive or operate machinery
  • Avoiding alcohol and other CNS depressants 1

Serotonin Syndrome: While hydroxyzine is not serotonergic, monitor for serotonin syndrome symptoms when starting escitalopram, especially if other serotonergic agents are present 2.

Monitoring Plan

  • Monitor for excessive sedation, particularly during initial weeks
  • Assess for cardiac symptoms (palpitations, syncope, dizziness)
  • Consider repeat ECG if dose escalation occurs or additional QT-prolonging drugs are added
  • Watch for signs of QT prolongation if electrolyte disturbances develop (vomiting, diarrhea, diuretic use)

Common Pitfall to Avoid

Do not dismiss the cardiac risk simply because both drugs are commonly prescribed. The additive QT prolongation effect is real, and while absolute risk remains low in patients without risk factors, it increases substantially in vulnerable populations (elderly, cardiac disease, electrolyte abnormalities, polypharmacy with other QT-prolonging agents).

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.